Balance Disorders News and Research

RSS

A balance disorder is a disturbance that causes an individual to feel unsteady, giddy, woozy, or have a sensation of movement, spinning, or floating. An organ in our inner ear, the labyrinth, is an important part of our vestibular (balance) system. The labyrinth interacts with other systems in the body, such as the visual (eyes) and skeletal (bones and joints) systems, to maintain the body's position. These systems, along with the brain and the nervous system, can be the source of balance problems.

Amgen gets positive CHMP opinions for Kyprolis (carfilzomib) and BLINCYTO (blinatumomab)

"We are pleased to receive positive CHMP opinions for Kyprolis and BLINCYTO as this is an important step in providing new treatment options for patients in Europe with rare forms of cancer," said Sean E. Harper, M.D., executive vice president of Research and Development at Amgen.

25 Sep 2015

Amgen, Xencor partner to develop and commercialize new therapeutics for cancer immunotherapy, inflammation

Amgen and Xencor, Inc. announced today that the two companies have entered into a research and license agreement to develop and commercialize novel therapeutics in the areas of cancer immunotherapy and inflammation.

16 Sep 2015

GenVec reports net loss of $1.9 million for second quarter 2015

GenVec, Inc. today reported financial results for the second quarter ended June 30, 2015. For the three months ended June 30, 2015, GenVec reported a net loss of $1.9 million, or $0.11 per share, on revenues of $0.1 million, compared with a net loss of $1.7 million, or $0.10 per share, on revenues of $0.1 million, for the same period in the prior year.

7 Aug 2015

Amgen to present clinical data on multiple blood cancer treatments at EHA 2015

Amgen today announced that it will present data from multiple Kyprolis (carfilzomib) for Injection, BLINCYTO (blinatumomab), oprozomib and Nplate (romiplostim)‎ studies at the 20th Congress of the European Hematology Association taking place in Vienna, June 11 - 14, 2015.

28 May 2015

$Brittle bones does not significantly affect occurrence of bone fractures among older people$

Brittle bones does not significantly affect occurrence of bone fractures among older people

Anti-osteoporotic medication is not an effective means for preventing hip fractures among the elderly, concludes a study recently published in the BMJ. According to Professor Teppo Järvinen from the University of Helsinki, who heads the research group, the prevalent assumption that brittle bones cause hip fractures is fundamentally flawed.

27 May 2015

GenVec reports net loss of $1.5 million for first quarter 2015

GenVec, Inc. today reported financial results for the first quarter ended March 31, 2015. For the three months ended March 31, 2015, GenVec reported a net loss of $1.5 million, or $0.09 per share, on revenues of $0.4 million, compared with a net loss of $1.0 million, or $0.07 per share, on revenues of $2.1 million, for the same period in the prior year.

8 May 2015

GenVec, Laboratory of Malaria Immunology and Vaccinology sign research collaboration agreement

GenVec, Inc. today announced that it has signed a research collaboration agreement with the Laboratory of Malaria Immunology and Vaccinology of the National Institute of Allergy and Infectious Diseases, National Institutes of Health.

21 Apr 2015

GenVec reports record financial results for Q4 and fiscal year 2014

GenVec, Inc. today reported financial results for the fourth quarter and year ended December 31, 2014. For the year ended December 31, 2014, the company reported a net loss of $2.5 million, or $0.16 per share, compared with a net loss of $10.0 million, or $0.77 per share, for the year ended December 31, 2013.

24 Mar 2015

GenVec collaborates with TheraBiologics to develop NSC-mediated cancer therapeutics

GenVec, Inc. today announced that it has formed a collaboration with TheraBiologics to develop cancer therapeutics leveraging both GenVec's proprietary gene delivery platform and TheraBiologics' proprietary neural stem cell (NSC) technology.

23 Mar 2015

Amgen announces new data from BLINCYTO Phase 2 study for treatment of patients with ALL

Amgen today announced that new data from a pivotal Phase 2 study evaluating BLINCYTO (blinatumomab) for the treatment of adult patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia (ALL) was presented at the 56th American Society of Hematology Annual Meeting and Exposition.

9 Dec 2014

Researchers create new vestibular test to add to comprehensive concussion evaluation

Researchers at UPMC and the University of Pittsburgh have created a new, 5- to 10-minute test that could be added to a clinician's concussion evaluation toolkit for a more comprehensive assessment of the injury.

11 Sep 2014

GenVec reports net loss of $1.7 million for second quarter 2014

GenVec, Inc. today reported financial results for the three-month and six-month periods ended June 30, 2014. For the three-month period ended June 30, 2014, the company reported a net loss of $1.7 million or $0.10 per share on revenues of $0.1 million as compared to a net loss of $3.1 million or $0.24 per share on revenues of $0.7 million in the same period in the prior year.

12 Aug 2014

UH Case Medical Center implants new type of cochlear device in patients with hearing problem

University Hospitals Case Medical Center is the first in Cleveland to implant a new type of cochlear device for adults who have lost the high frequency range of their hearing, but have retained the low frequencies with or without a hearing aid.

7 Aug 2014

GenVec's revenues decrease 61% to $3.7M in fourth quarter 2013

GenVec, Inc. today reported financial results for the fourth quarter and year ended December 31, 2013. For the year ended December 31, 2013, the company reported a net loss of $10.0 million, or $0.77 per share, compared with a net loss of $14.1 million, or $1.09 per share, for the year ended December 31, 2012.

28 Mar 2014

Vestibular system is critical for optimizing head and eye movements

Neurologists at Ludwig-Maximilians-Universitaet (LMU) in Munich have studied the role of the vestibular system, which controls balance, in optimizing how we direct our gaze. The results could lead to more effective rehabilitation of patients with vestibular or cerebellar dysfunction.

25 Mar 2014

MRI magnetic fields may diagnose, treat balance disorders and dizziness, say researchers

Expanding on earlier research, Johns Hopkins researchers report that people with balance disorders or dizziness traceable to an inner-ear disturbance show distinctive abnormal eye movements when the affected ear is exposed to the strong pull of an MRI’s magnetic field.

20 Mar 2014

Surgeons perform first auditory brainstem implant operation in Northeast Ohio

Surgeons at University Hospitals Case Medical Center have completed the first auditory brainstem implant (ABI) operation in Northeast Ohio on a woman who has lost most of her hearing due to benign tumors on her auditory nerves.

17 Mar 2014

GenVec achieves third milestone for development of treatments for hearing and balance disorderstion

GenVec, Inc. (NASDAQ: GNVC) today announced that the company has achieved the third milestone in its collaboration with Novartis for the development of treatments for hearing and balance disorders.

13 Feb 2014

Doctors receive €3.5M European Union funding to diagnose, treat balance disorders

GPs and other doctors will be equipped with a new, online information system to help diagnose and treat a range of balance disorders, thanks to €3.5m European Union funding for EMBalance.

12 Feb 2014

Research opens door to better understanding of inner-ear development process, potential treatments

Indiana University scientists have transformed mouse embryonic stem cells into key structures of the inner ear. The discovery provides new insights into the sensory organ's developmental process and sets the stage for laboratory models of disease, drug discovery and potential treatments for hearing loss and balance disorders.

12 Jul 2013